An 18-Month Study to Assess the Safety, Tolerability, and Efficacy of MK0364 in Obese Patients.
Phase of Trial: Phase II/III
Latest Information Update: 15 Jun 2016
At a glance
- Drugs Taranabant (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 22 Sep 2009 Trial phase changed from II to II/III as reported by ClinicalTrials.gov.
- 17 May 2008 Interim results were reported at the 16th European Congress on Obesity.
- 14 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History